Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, has announced the granting of 566 restricted stock units (RSUs) to two newly-hired employees. These awards are part of the company's 2022 Inducement Stock Incentive Plan and were granted on May 31, 2025. Each RSU will vest over three years, with one-third of the shares vesting on each anniversary of the grant date, contingent upon continued service with the company. Additionally, in the event of a "change in control event," the RSUs will fully vest if the employee is terminated for "good reason" or without "cause" within one year of the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE98023) on June 02, 2025, and is solely responsible for the information contained therein.